Dermatology News & Information
Yale Dermatology Honors Jean Bolognia, MD
With a career at Yale spanning more than 40 years, Vice Chair of Faculty Affairs and Professor of Dermatology Jean Bolognia, MD, is a 'Yalie' through and through. Here at Yale Dermatology, we are proud to call her an esteemed colleague who has contributed immeasurably to our field.
Dr. Bolgonia has been part of the fabric of our YSM community for decades. Having received her medical degree from YSM in 1980, she remained as trainee and then in her subsequent professorship and leadership roles within the Department of Dermatology. When asked by the Yale Journal of Biological Science what stands out about YSM, she applauded the cohesive faculty and Grand Rounds live patient viewing as unique models for both nurturing a sense of collegiality among faculty and providing an accurate and authentic training environment.
As a clinician-educator, Dr. Bolognia leads with compassion. She is adept at guiding patients with a history of cutaneous melanoma through concerning diagnoses and involves both patients and their loved ones in the treatment process. She also notably coined "toxic erythema of chemotherapy," a term which enables physicians to hone in on a diagnosis more efficiently as a team. Having benefited from the wisdom of great educators in her own life, she is celebrated for having mentored countless individuals, from trainees to colleagues.
Dr. Bolognia has received a multitude of national and international awards, and she has held leadership positions at several organizations. This includes having served as president of the Medical Dermatology Society, Women's Dermatologic Society, and American Dermatological Society, respectively. Her greatest accomplishment to date, however, is being senior editor of Dermatology (Elsevier). Now in its fifth edition, this textbook offers a streamlined approach to dermatology pedagogy, breaking down complex topics and utilizing schematics to introduce dermatologic principles.
In her spare time, Dr. Bolognia enjoys gardening, traveling, reading, impressionist art, and Motown.
Christine Ko, MD, has made a lead gift to honor Dr. Bolognia and her remarkable career and is leading our efforts to create an endowed professorship in her name. To join Dr. Ko and others with your support, please contact our development partner, Aliza Elwell, or make a gift online. Please be sure to write "Bolognia Endowment" in the free text field.
Sources:
"Pioneers in Dermatology and Venereology: An Interview with Professor Jean L. Bolognia"
"Learning from a Trailblazer in Dermatology: An Interview with Jean Bolognia, MD"
A Piece of Yale Dermatology History
A photographic celebration of the history and growth of Yale Dermatology through the decades. We are pleased to display this restored collection of faculty photos in the Lippard Lab of Clinical Investigation outside the Dermatology administrative suite.
New Appointments and Promotions
Instructor of Dermatology
Robert Stavert, MD, joined our faculty as an instructor of dermatology in March. He completed medical school at Yale School of Medicine (YSM), internship at Beth Israel Deaconess Medical Center, and dermatology residency at Yale New Haven Hospital. After Yale, Stavert wroked in the Boston area for about 10 years before recently relocating back to Connecticut, and is currently working at the Cornell Scott Hill Health Center. He is grateful for the opportunity to serve the patients there and to be part of the Yale Dermatology community.
Assistant Professor
Sarah Kim, MD, joined the dermatologic surgery faculty as an assistant professor of dermatology in September. She received her MD from Yale School of Medicine, graduating cum laude, and she completed her dermatology residency at Yale New Haven Hospital. During her residency, she discovered her keen interests in dermatologic surgery and cutaneous oncology. Kim also demonstrated her passion for education as the resident representative for the Graduate Medical Education Committee, the resident board member for the Association of Academic Cosmetic Dermatologists, and a biomedical engineering course instructor at Yale. Her interests include dermatologic surgery, cutaneous oncology, aesthetic dermatology, melasma, and skin of color.
Outside her professional life, she enjoys exploring the culinary scene and spending quality time with her cats and her husband, Minu.
Assistant Professor
Lihi Atzmony Maoz, MD, joined our faculty in July as an assistant professor of dermatology specializing in non-melanoma skin cancer and genetic skin diseases. She obtained her MD from Tel Aviv University in 2011 and completed her dermatology residency at Rabin Medical Center, Israel.
Following her residency, Atzmony Maoz pursued a post-doctoral fellowship in genetic skin diseases at Yale School of Medicine. Beginning in 2019, she had served as an attending dermatologist at Rabin Medical Center, Israel, and as the director of the Genetic Skin Diseases and of the Advanced Non-Melanoma Skin Cancer Clinics. Her research interests include new treatment modalities for NMSC, pathogenesis-based therapies, and genetic skin diseases.
In addition to mentoring medical students and dermatology residents, Atzmony Maoz has demonstrated her commitment to education through various roles, having served as the director of the Dermatology CME program at Tel Aviv University and the dermatology residency program director at Rabin Medical Center.
Assistant Professor
Goran Micevic, MD, PhD, has been appointed assistant professor of clinical dermatology and dermatopathology, having demonstrated a track record of innovative scientific work. Micevic completed his undergraduate and graduate training at Yale School of Medicine, including his MD, cum laude; PhD in immunobiology with honors; dermatology residency; and dermatopathology fellowship.
Micevic is a superb dermatologist and dermatopathologist whose abilities complement and expand the skills of our existing team. At the most recent national dermatopathology meeting, he was awarded first place for his work regarding histopathologic markers of response to immune checkpoint therapy in melanoma. His research contributions in developing new treatment modalities and biomarkers for melanoma and cutaneous malignancies have been recognized with numerous awards, most recently including the Dermatology Foundation Career Development Award and the American Society for Clinical Investigation Emerging Generation Award. His goal is to bring cutting-edge molecular advancements from the lab to the microscope and clinic to improve treatment and diagnostic and prognostic accuracy of skin cancers.
Assistant Professor
Starling D. Haynes, MD, most recently served as chief resident at Wayne State University in Detroit, Michigan. She obtained both her BS and medical degree from The Ohio State University. Throughout her residency, she took on the role of chair for the Justice, Equity, Diversity, and Inclusion (JEDI) Committee, impacting initiatives at both the resident program and GME level. She spearheaded multiple DEI efforts, such as implementing a health disparities curriculum; conducting community outreach to underrepresented in medicine (URiM) elementary and high schools, which benefited more than 1,000 students; establishing a dermatology-specific free clinic; and creating a comprehensive recruitment and interview guide used across all Wayne State GME residency programs. Her diverse clinical interests encompass hair loss in afro-textured hair, skin of color, hidradenitis suppurativa, surgical dermatology, teledermatology, and aesthetic dermatology.
Clinical Fellow
Andrew Johnston, MD, PhD, will continue his post-doctoral work in the lab of John Tsang, PhD, MMath, applying a systems vaccinology approach to establish a model of human skin inflammation induction and memory. He is also seeing patients at the new Madison office. He is grateful for the opportunity to push forward scientific knowledge and serve patients as part of the Yale Dermatology community
Latest News
FDA Accepts LEO Pharma's Filing of Delgocitinib Cream New Drug Application for the Treatment of Chronic Hand Eczema
“Dermatologists regularly see the true extent to which CHE impacts patients’ lives through unique physical and psychological challenges,” said Christopher Bunick, MD, PhD, Associate Professor of Dermatology, Yale Medical School . “Many patients need more options beyond traditional topical corticosteroid use, so I welcome today’s news, which brings the prospect of a potential new treatment option one step closer for those across the U.S. living with this debilitating condition.”
Source: The Associated Press23 Sep 2024Yale Research Highlights Unmet Needs for Patients With Melanoma Who Progress or Relapse After Immunotherapy Treatment
A retrospective cohort study by Yale Cancer Center researchers of nearly 200 patients with melanoma who died after receiving treatment with immunotherapy highlights a need to improve outcomes for patients who progress or relapse after the treatment.
30 Aug 2024The Best and Worst Ways to Get Rid of Blackheads
Popping blackheads will only make matters worse. We consulted board-certified dermatologists for their tips on removing your blackheads and clearing up your skin.
Source: Everyday Health16 Aug 20245 Dermatologists on the 1 Thing You Should Do Every Day
Assistant Professor of Dermatology Sara Perkins, MD, and other dermatologists agree that applying broad spectrum sunscreen of at least 30 SPF is the best thing people can do to promote healthy skin every day. They also provide some bonus skincare tips.
Source: TIME13 Aug 2024Hyaluronic Acid Lip Fillers Safe for Patients with Systemic Sclerosis
Hyaluronic acid lip fillers are safe and effective for patients with systemic sclerosis, or scleroderma, a new Yale study finds. The study was directed by Kathleen Suozzi, MD, associate professor of dermatology, and Monique Hinchcliff, MD, MS, associate professor of medicine (rheumatology, allergy & immunology) and director of the Yale Scleroderma Program.
15 Jul 2024National Academy of Medicine Elects Two From Yale School of Medicine
Erol Fikrig, MD, is honored for his work leading to a Lyme disease vaccine, and Haifan Lin, PhD, is recognized for two "hallmark" stem cell theories.
21 Oct 2024The Internet Is Obsessed With This Face Mask That Claims To Boost Collagen. Is It Legit?
Dermatologists share their honest thoughts on this buzzy skin care product.
Source: HuffPost30 Sep 2024Eczema risk seems to increase from polluted air, study finds
Living in places with more air pollution raises the risk of eczema, a chronic condition that causes dry, itchy and inflamed skin, a new study suggests.
Source: Yahoo13 Nov 20245 common skin rashes that can be caused by COVID, according to dermatologists
Some viral illnesses are known to cause rashes, like hives.
Source: NBC Chicago10 Nov 20245 COVID skin rashes: Dermatologists share tips to identify and treat viral skin conditions
Some viral illnesses are known to cause rashes, like hives.
Source: TODAY9 Nov 2024Expert tips for dry, wintery skin
Jeffrey Cohen, MD, assistant professor of dermatology and biomedical informatics and data science; director, Psoriasis Treatment Program; and director of safety, dermatology, describes recent research that found that people with eczema (or atopic dermatitis) have a higher likelihood of developing peripheral artery disease. He also expanded on the correlation between psoriasis and obsessive compulsive disorder and offered skincare tips for the winter months.
Source: WTNH News88 Nov 2024What Does Skin Cancer Look Like on Black Skin?
Skin cancer looks different on Black skin, often leading to delayed diagnoses. Learn how it appears, risk factors, and prevention tips to aid early detection.
Source: Everyday Health24 Oct 2024Is It Safe to Dermaplane My Face?
Associate Professor Kathleen Suozzi, MD, and experts weigh the benefits and risks of dermaplaning and evaluate the procedure's efficacy when performed by a professional versus at home.
Source: The New York Times1 Oct 2024An Introduction to Cutaenous T-cell Lymphoma
Michael Girardi, MD, vice chair for faculty development and scientific innovation; Evans Professor of Dermatology; and co-director, T32 research fellowship program, gives a virtual patient education presentation entitled "An Introduction to Cutaneous T-cell Lymphoma" for the Cutaneous Lymphoma Foundation.
Source: Cutaneous Lymphoma Foundation/YouTube30 Jul 2024An Introduction to Therapies for Cutaneous T-cell Lymphoma
Michael Girardi, MD, vice chair for faculty development and scientific innovation; Evans Professor of Dermatology; and co-director, T32 research fellowship program, gives a virtual patient education presentation entitled, "An Introduction to Therapies for Cutaneous T-cell Lymphoma" for the Cutaneous Lymphoma Foundation.
Source: Cutaneous Lymphoma Foundation/YouTube30 Jul 2024Basic Science Research for Cutaneous T-cell Lymphoma
Michael Girardi, MD, vice chair for faculty development and scientific innovation; Evans Professor of Dermatology; and co-director, T32 research fellowship program, gives a virtual patient education presentation entitled, "Basic Science Research for CTCL: Advancing Our Understanding & Treatment" for the Cutaneous Lymphoma Foundation.
Source: Cutaneous Lymphoma Foundation/YouTube30 Jul 2024Clinical Q&A - Virtual Patient Educational Forum 2024
Francine Foss, MD; Michael Girardi, MD; and Tarsheen Sethi, MD, MSc, all Yale School of Medicine faculty members, were part of an expert panel during a virtual Q&A session regarding cutaneous lymphoma for the Cutaneous Lymphoma Foundation.
Source: Cutaneous Lymphoma Foundation/YouTube30 Jul 2024Unexpected Findings in Study of T Cells, Considered Front-line Fighters Against Advanced Melanoma
The study by Yale Cancer Center (YCC) researchers at Yale School of Medicine (YSM) discovered that not all CD8+ T cells are allies in a body’s fight against cancer cells. In a new study, patients living with severe melanoma who had increased levels of suppressor, regulatory CD8+ T cells had worse survival outcomes.
28 Nov 2024Dr. Francine Foss on Yale Cancer Answers: Groundbreaking Treatment for a Rare Lymphoma
On Sunday, November 17, 2024, Dr. Eric Winer interviewed Francine Foss, MD, Professor of Medicine (Hematology) and of Dermatology. Dr. Foss is an internationally recognized clinician and clinical researcher with expertise in adult lymphomas and in stem cell transplantation.
18 Nov 2024
Publications
- 7418 Xanthoma Disseminatum - A Rare cause of Diabetes InsipidusBalasubramanian P, Cohen J, Corbin Z, Panse G, Inzucchi S. 7418 Xanthoma Disseminatum - A Rare cause of Diabetes Insipidus. Journal Of The Endocrine Society 2024, 8: bvae163.1380. PMCID: PMC11454384, DOI: 10.1210/jendso/bvae163.1380.
- Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder CancerLerner S, Tangen C, Svatek R, Daneshmand S, Pohar K, Skinner E, Schuckman A, Sagalowsky A, Smith N, Kamat A, Kassouf W, Plets M, Bangs R, Koppie T, Alva A, La Rosa F, Pal S, Kibel A, Canter D, Thompson I. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. New England Journal Of Medicine 2024, 391: 1206-1216. PMID: 39589370, PMCID: PMC11599768, DOI: 10.1056/nejmoa2401497.
- Validation of the Delphi Consensus Diagnostic Criteria for Necrobiotic XanthogranulomaBassir F, Valido K, Maciejewski K, Damsky W, Nelson C. Validation of the Delphi Consensus Diagnostic Criteria for Necrobiotic Xanthogranuloma. JAMA Dermatology 2024, 160: 1361-1362. PMID: 39356540, PMCID: PMC11447626, DOI: 10.1001/jamadermatol.2024.3198.
- Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia AreataKing B, Ko J, Kwon O, Vañó-Galván S, Piraccini B, Dutronc Y, Yu G, Liu C, Somani N, Ball S, Mesinkovska N. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata. JAMA Dermatology 2024, 160: 1075-1081. PMID: 39141364, PMCID: PMC11325239, DOI: 10.1001/jamadermatol.2024.2734.
- Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis.Daniele S, Galimberti F, Bunick C. Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis. Journal Of Drugs In Dermatology 2024, 23: 903-904. PMID: 39361690.
- Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis.Lain E, Bhatia N, Kircik L, Gold L, Harper J, Bunick C, Guenin E, Baldwin H, Feldman S, Rosso J. Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis. Journal Of Drugs In Dermatology 2024, 23: 873-881. PMID: 39361705, DOI: 10.36849/jdd.2024.8484.
- Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate CancerGoldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J, Ingles S, Triche T, MacVicar G, Vaena D, Crispino A, McConkey D, Lara P, Hussain M, Quinn D, Dorff T, Lerner S, Thompson I, Agarwal N. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Network Open 2024, 7: e2437871. PMID: 39374015, PMCID: PMC11581504, DOI: 10.1001/jamanetworkopen.2024.37871.
- Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug ProductsKucera K, Zenzola N, Hudspeth A, Dubnicka M, Hinz W, Bunick C, Girardi M, Dabestani A, Light D. Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products. Journal Of Investigative Dermatology 2024 PMID: 39384016, DOI: 10.1016/j.jid.2024.09.009.
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalisMesinkovska N, King B, Zhang X, Guttman‐Yassky E, Magnolo N, Sinclair R, Mizuashi M, Shapiro J, Peeva E, Banerjee A, Takiya L, Cox L, Wajsbrot D, Kerkmann U, Law E, Wolk R, Schaefer G. Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis. The Journal Of Dermatology 2024, 51: 1414-1424. PMID: 39328096, DOI: 10.1111/1346-8138.17442.
- Perioral hyaluronidase injection for the treatment of microstomia in systemic sclerosis patients: A retrospective cohort studyElgash M, Kim S, Swallow M, Hinchcliff M, Suozzi K. Perioral hyaluronidase injection for the treatment of microstomia in systemic sclerosis patients: A retrospective cohort study. Journal Of The American Academy Of Dermatology 2024, 92: 148-150. PMID: 39307355, DOI: 10.1016/j.jaad.2024.09.019.
- IL-1β Induces Human Endothelial Surface Expression of IL-15 by Relieving let-7c-3p Suppression of Protein Translation.Mullan C, Summer L, Lopez-Giraldez F, Tobiasova Z, Manes T, Yasothan S, Song G, Jane-Wit D, Saltzman W, Pober J. IL-1β Induces Human Endothelial Surface Expression of IL-15 by Relieving let-7c-3p Suppression of Protein Translation. The Journal Of Immunology 2024, 213: 1338-1348. PMID: 39302113, PMCID: PMC11493510, DOI: 10.4049/jimmunol.2400331.
- Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analysesPeeva E, Yamaguchi Y, Ye Z, King B, Picardo M, Sloan A, Ezzedine K, Del Duca E, Estrada Y, Hassan‐Zahraee M, He W, Hyde C, Bar J, Facheris P, Guttman‐Yassky E. Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses. Experimental Dermatology 2024, 33: e15177. PMID: 39304339, DOI: 10.1111/exd.15177.
- Development of an Objective Structured Assessment of Technical Skills for SclerotherapyMa M, Zafar F, Goldman M, Munavalli G, Zimmet S, Nguyen T, Mishra V, Cartee T, Mann M, Hsu J, Silapunt S, Weiss R, Weiss M, Haq M, Ahmed A, Koza E, Shi V, Dave L, Yi M, Kang B, Cahn B, Bae Y, Kole L, Friedmann D, Chow M, Minkis K, Stücker M, Schlick C, Hoss E, Hu J, Kibbi N, Saikaly S, Greywal T, Hooper D, Vashi N, Boucher A, Ward K, Neuhaus I, Ghareeb E, Luke J, Karen J, Suggs A, Lucas J, Decker A, Brieva J, Yoo S, Suozzi K, Alam M. Development of an Objective Structured Assessment of Technical Skills for Sclerotherapy. Journal Of The American Academy Of Dermatology 2024, 92: 129-132. PMID: 39288871, DOI: 10.1016/j.jaad.2024.08.062.
- Abstract PR-01: Systemic targeting of therapeutic RNA to pancreatic ductal adenocarcinoma via a novel, cell-penetrating, and nucleic acid-binding monoclonal antibodyMartinez-Saucedo D, Quijano E, Ianniello Z, Rackear M, Liu Y, Hegan D, Chen H, Shan X, Tseng R, Yugawa D, Pinto-Medici N, Chowdhury S, Bindra R, Robert M, Saltzman W, Escobar-Hoyos L, Glazer P. Abstract PR-01: Systemic targeting of therapeutic RNA to pancreatic ductal adenocarcinoma via a novel, cell-penetrating, and nucleic acid-binding monoclonal antibody. Cancer Research 2024, 84: pr-01-pr-01. DOI: 10.1158/1538-7445.pancreatic24-pr-01.
- Retrospective analysis of nail findings in the National Registry for Ichthyosis and Related Disorders databaseCurtis K, Echeandia-Francis C, Falotico J, Luo A, Qiu Y, Grover C, Piraccini B, Choate K, Lipner S. Retrospective analysis of nail findings in the National Registry for Ichthyosis and Related Disorders database. Journal Of The American Academy Of Dermatology 2024, 92: 132-134. PMID: 39278313, DOI: 10.1016/j.jaad.2024.08.063.
- Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell CarcinomaBarata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, 42: 3911-3916. PMID: 39255440, PMCID: PMC11575905, DOI: 10.1200/jco.24.00767.
- Real World Data on Efficacy and Safety of EPOCH in T-Cell LymphomaStraining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.
- Clinical and Histologic Variants of CD8+ Cutaneous T-Cell LymphomasSwallow M, Micevic G, Zhou A, Carlson K, Foss F, Girardi M. Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas. Cancers 2024, 16: 3087. PMID: 39272944, PMCID: PMC11394026, DOI: 10.3390/cancers16173087.
- Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 TrialMaruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Narita T, Foss F, Yamauchi N, Yuda J, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Inoue A, Tachibana M, Hizukuri Y, Horwitz S, Jacobsen E. Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s229. DOI: 10.1016/s2152-2650(24)00908-x.
- TCL-391 Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 TrialMaruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Narita T, Foss F, Yamauchi N, Yuda J, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Maruyama A, Tachibana M, Hizukuri Y, Horwitz S, Jacobsen E. TCL-391 Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s523-s524. DOI: 10.1016/s2152-2650(24)01617-3.
- 50170 Cross-Sectional Survey of Hands-on Cosmetic and Laser Training in Dermatology ResidencyKang B, Minkis K, Suozzi K, Greywal T, Hoss E, Bolotin D, Kibbi N, Alam M. 50170 Cross-Sectional Survey of Hands-on Cosmetic and Laser Training in Dermatology Residency. Journal Of The American Academy Of Dermatology 2024, 91: ab170. DOI: 10.1016/j.jaad.2024.07.677.
- 285 Development of an electrochemiluminescence CFTR immunoassayBrowne J, Lee J, Peterec K, Garrison A, Bruscia E, Saltzman W, Egan M. 285 Development of an electrochemiluminescence CFTR immunoassay. Journal Of Cystic Fibrosis 2024, 23: s152. DOI: 10.1016/s1569-1993(24)01125-1.
- 264 Poly(amine-co-ester) nanoparticle delivery of CFTR mRNA shows restoration of CFTR activity in cystic fibrosis airway modelsGarrison A, Lee J, Browne J, Akhtar L, Peterec K, Suberi A, Eaton D, Ene M, Zhang X, Whang C, Oez H, Kizilirmak T, Bruscia E, Piotrowski-Daspit A, Saltzman W, Egan M. 264 Poly(amine-co-ester) nanoparticle delivery of CFTR mRNA shows restoration of CFTR activity in cystic fibrosis airway models. Journal Of Cystic Fibrosis 2024, 23: s140-s141. DOI: 10.1016/s1569-1993(24)01104-4.
- 295 Polymeric nanoparticles for in utero gene delivery in non-human primatesPiotrowski-Daspit A, Lynn A, Eaton D, Bracaglia L, Mortlock R, Tarantal A, Glazer P, Saltzman W. 295 Polymeric nanoparticles for in utero gene delivery in non-human primates. Journal Of Cystic Fibrosis 2024, 23: s157. DOI: 10.1016/s1569-1993(24)01135-4.
- 54712 Bipolar disorder among patients with atopic dermatitis: A case-control study in the All of Us research programWride M, Chen G, Fan R, Leasure A, Levey D, Damsky W, Cohen J. 54712 Bipolar disorder among patients with atopic dermatitis: A case-control study in the All of Us research program. Journal Of The American Academy Of Dermatology 2024, 91: ab147. DOI: 10.1016/j.jaad.2024.07.584.
- 53614 Stigma drives mental health issues in children and adolescents with vitiligoYang L, Rangel S, Griffith J, Chamlin S, Paller A, Hogeling M, Schoch J, FAAD, Rehmus W, Castelo-Soccio L, Antaya R. 53614 Stigma drives mental health issues in children and adolescents with vitiligo. Journal Of The American Academy Of Dermatology 2024, 91: ab317. DOI: 10.1016/j.jaad.2024.07.1260.
- 51523 The Phase 3 Vehicle-Controlled ASCEND Trial of Polyethylene Glycol Based Topical Isotretinoin (TMB-001 0.05% ointment) for Treatment of X-Linked and Autosomal Recessive Congenital Ichthyosis: Pharmacokinetic Results Compared with 80 mg Oral IsotretinoinBunick C, Huynh T, Jackson M, Lee L, Kempers S, Mendelsohn A, Eursken B, Ahson A, Raiz J, MC. Teng J. 51523 The Phase 3 Vehicle-Controlled ASCEND Trial of Polyethylene Glycol Based Topical Isotretinoin (TMB-001 0.05% ointment) for Treatment of X-Linked and Autosomal Recessive Congenital Ichthyosis: Pharmacokinetic Results Compared with 80 mg Oral Isotretinoin. Journal Of The American Academy Of Dermatology 2024, 91: ab332. DOI: 10.1016/j.jaad.2024.07.1321.
- 49169 Impact of secukinumab on high-sensitivity C-reactive protein and erythrocyte sedimentation rate: Post hoc analysis of pooled data from the SUNSHINE and SUNRISE Phase 3 randomized trialsvan Straalen K, Bunick C, Lobach I, Uhlmann L, Passera A, Alarcon I, Wozniak M, Ravichandran S, Martinez A, da Costa A, Bechara F. 49169 Impact of secukinumab on high-sensitivity C-reactive protein and erythrocyte sedimentation rate: Post hoc analysis of pooled data from the SUNSHINE and SUNRISE Phase 3 randomized trials. Journal Of The American Academy Of Dermatology 2024, 91: ab235. DOI: 10.1016/j.jaad.2024.07.932.
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 TrialsSenna M, King B, Mesinkovska N, Mostaghimi A, Hamilton C, Cassella J. 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials. Journal Of The American Academy Of Dermatology 2024, 91: ab39. DOI: 10.1016/j.jaad.2024.07.161.
- 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areataMostaghimi A, Augustin M, Harada K, Senna M, Dutronc Y, Yu G, Ball S, Murage M, Kolodsick J, King B. 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata. Journal Of The American Academy Of Dermatology 2024, 91: ab15. DOI: 10.1016/j.jaad.2024.07.071.
- 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2Senna M, Mostaghimi A, Ohyama M, Sinclair R, Chiasserini C, Dutronc Y, Somani N, Yu G, Kolodsick J, King B. 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2. Journal Of The American Academy Of Dermatology 2024, 91: ab251. DOI: 10.1016/j.jaad.2024.07.996.
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical TrialsKing B, Mostaghimi A, Ohyama M, Senna M, Chiasserini C, Dutronc Y, Liu C, Yu G, Murage M, Sinclair R. 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials. Journal Of The American Academy Of Dermatology 2024, 91: ab69. DOI: 10.1016/j.jaad.2024.07.282.
- 52874 Timing of eyebrow and eyelash regrowth among subgroups of scalp responders during treatment of severe alopecia areata with baricitinibKing B, Senna M, Ohyama M, Dutronc Y, Lu N, Chiasserini C, Somani N, Piraccini B. 52874 Timing of eyebrow and eyelash regrowth among subgroups of scalp responders during treatment of severe alopecia areata with baricitinib. Journal Of The American Academy Of Dermatology 2024, 91: ab340. DOI: 10.1016/j.jaad.2024.07.1353.
- Collaborative management of specialty medications by a dermatologist and pharmacist: a retrospective cohort pilot studySpaulding S, Slade M, Tong K, Stroedecke N, Shin H, Cohen J. Collaborative management of specialty medications by a dermatologist and pharmacist: a retrospective cohort pilot study. International Journal Of Dermatology 2024, 63: e361-e363. PMID: 39212107, PMCID: PMC11490358, DOI: 10.1111/ijd.17462.
- Hepatitis C and its treatment in patients with psoriasis: a propensity-matched case-control studyZhu H, Shaw V, Cohen J. Hepatitis C and its treatment in patients with psoriasis: a propensity-matched case-control study. Archives Of Dermatological Research 2024, 316: 580. PMID: 39207533, DOI: 10.1007/s00403-024-03340-2.
- Risk of developing inflammatory arthritis in patients with psoriasis initiating treatment with biologics: A population-based analysisStrober B, Soliman A, Li C, Patel M, Unigwe I, Gisondi P. Risk of developing inflammatory arthritis in patients with psoriasis initiating treatment with biologics: A population-based analysis. Journal Of The American Academy Of Dermatology 2024, 91: 1143-1149. PMID: 39197499, DOI: 10.1016/j.jaad.2024.06.106.
- Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancerTaylor J, Kamat A, O'Donnell M, Annapureddy D, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer. BJU International 2024 PMID: 39183466, DOI: 10.1111/bju.16509.
- Statins Inhibit Cutaneous Squamous Cell Carcinoma CellsHACKETT A, COHEN A, RUTENBERG T, HODAK E, MOYAL L, ATZMONY L. Statins Inhibit Cutaneous Squamous Cell Carcinoma Cells. Acta Dermato Venereologica 2024, 104: 25097. PMID: 39185545, PMCID: PMC11367778, DOI: 10.2340/actadv.v104.25097.
- Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient SelectionLi R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, Brausi M, Bree K, Fernández M, Guo C, Horowitz A, Lamm D, Lerner S, Lotan Y, Mariappan P, McConkey D, Mertens L, Mir C, Ross J, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess P, Svatek R, Tan W, Taoka R, Buckley R, Kamat A. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. European Urology 2024, 86: 516-527. PMID: 39183090, DOI: 10.1016/j.eururo.2024.08.001.
- Cross-tissue organization of myeloid cells in scleroderma and related fibrotic diseasesOdell I. Cross-tissue organization of myeloid cells in scleroderma and related fibrotic diseases. Current Opinion In Rheumatology 2024, 36: 379-386. PMID: 39171604, PMCID: PMC11451931, DOI: 10.1097/bor.0000000000001047.
- Chemiexcitation in preventing macular degenerationBrash D, Gaillard E. Chemiexcitation in preventing macular degeneration. Frontiers In Photonics 2024, 5: 1451857. DOI: 10.3389/fphot.2024.1451857.
- Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correctionLi X, Liu T, Bacchiocchi A, Li M, Cheng W, Wittkop T, Mendez F, Wang Y, Tang P, Yao Q, Bosenberg M, Sznol M, Yan Q, Faham M, Weng L, Halaban R, Jin H, Hu Z. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. EMBO Molecular Medicine 2024, 16: 2188-2209. PMID: 39164471, PMCID: PMC11393307, DOI: 10.1038/s44321-024-00115-0.
- Alterations in the Skin Microbiome in Dermatologic Diseases and with External Exposures: CME Part 2MacGibeny M, Adjei S, Pyle H, Bunick C, Ghannoum M, Grada A, Harris-Tryon T, Tyring S, Kong H. Alterations in the Skin Microbiome in Dermatologic Diseases and with External Exposures: CME Part 2. Journal Of The American Academy Of Dermatology 2024 PMID: 39173885, DOI: 10.1016/j.jaad.2024.07.1499.
- The Human Skin Microbiome in Health: CME Part 1MacGibeny M, Adjei S, Pyle H, Bunick C, Ghannoum M, Grada A, Harris-Tryon T, Tyring S, Kong H. The Human Skin Microbiome in Health: CME Part 1. Journal Of The American Academy Of Dermatology 2024 PMID: 39168311, DOI: 10.1016/j.jaad.2024.07.1498.
- The human CD47 checkpoint is targeted by an immunosuppressive Aedes aegypti salivary factor to enhance arboviral skin infectivityMarin-Lopez A, Huck J, Esterly A, Azcutia V, Rosen C, Garcia-Milian R, Sefik E, Vidal-Pedrola G, Raduwan H, Chen T, Arora G, Halene S, Shaw A, Palm N, Flavell R, Parkos C, Thangamani S, Ring A, Fikrig E. The human CD47 checkpoint is targeted by an immunosuppressive Aedes aegypti salivary factor to enhance arboviral skin infectivity. Science Immunology 2024, 9: eadk9872. PMID: 39121194, DOI: 10.1126/sciimmunol.adk9872.
- Long COVID science, research and policyAl-Aly Z, Davis H, McCorkell L, Soares L, Wulf-Hanson S, Iwasaki A, Topol E. Long COVID science, research and policy. Nature Medicine 2024, 30: 2148-2164. PMID: 39122965, DOI: 10.1038/s41591-024-03173-6.
- Mechanistic Basis for the Translation Inhibition of Cutibacterium acnes by ClindamycinLomakin I, Devarkar S, Grada A, Bunick C. Mechanistic Basis for the Translation Inhibition of Cutibacterium acnes by Clindamycin. Journal Of Investigative Dermatology 2024, 144: 2553-2561.e3. PMID: 39122144, DOI: 10.1016/j.jid.2024.07.013.
- Enhanced intratumoral delivery of immunomodulator MPLA via hyperbranched polyglycerol-coated biodegradable nanoparticlesChang J, Shin K, Lewis J, Suh H, Lee J, Damsky W, Xu S, Bosenberg M, Saltzman W, Girardi M. Enhanced intratumoral delivery of immunomodulator MPLA via hyperbranched polyglycerol-coated biodegradable nanoparticles. Journal Of Investigative Dermatology 2024 PMID: 39122142, DOI: 10.1016/j.jid.2024.07.019.
- 683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based studyBunick C, Grada A, Del Rosso J, Armstrong A, Yue E, Krueger W. 683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study. British Journal Of Dermatology 2024, 191: ljae266.057. DOI: 10.1093/bjd/ljae266.057.
- 734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up)Silverberg J, Bunick C, Hong H, Mendes-Bastos P, Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Eyerich K. 734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up). British Journal Of Dermatology 2024, 191: ljae266.107. DOI: 10.1093/bjd/ljae266.107.
- 681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims dataVleugels R, Grada A, Yue E, Bunick C, Galimberti F, Krueger W. 681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.055. DOI: 10.1093/bjd/ljae266.055.
- 696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studiesPrajapati V, Bunick C, Eyerich K, Gold L, Galimberti F, Calimlim B, Teixeira H, Hu X, Yang Y, Sancho C, Grada A, Irvine A. 696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies. British Journal Of Dermatology 2024, 191: ljae266.070. DOI: 10.1093/bjd/ljae266.070.
- 697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims dataLebwohl M, Yue E, Krueger W, Berman B, Bunick C, Schlesinger T, Grada A. 697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.071. DOI: 10.1093/bjd/ljae266.071.
- 706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP studySilverberg J, Calimlim B, Fuxench Z, Altman K, Bensimon A, Liu J, Bunick C. 706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study. British Journal Of Dermatology 2024, 191: ljae266.080. DOI: 10.1093/bjd/ljae266.080.
- 640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitisBunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 191: ljae266.021. DOI: 10.1093/bjd/ljae266.021.
- 699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based studyMostaghimi A, Armstrong A, Grada A, Soliman A, Li C, C Bristow C, Lipiszko D, Silverberg J, Issa N, Bunick C. 699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study. British Journal Of Dermatology 2024, 191: ljae266.073. DOI: 10.1093/bjd/ljae266.073.
- Plasma collagen neoepitopes are associated with multiorgan disease in the ACCESS and GRADS sarcoidosis cohortsSand J, Jessen H, Leeming D, Yu S, Lee C, Hu B, Sun Y, Adams T, Pivarnik T, Liu A, Woo S, McGovern J, Fiorini V, Saber T, Higuero-Sevilla J, Gulati M, Kaminski N, Damsky W, Shaw A, Mohanty S, Goobie G, Zhang Y, Herzog E, Ryu C. Plasma collagen neoepitopes are associated with multiorgan disease in the ACCESS and GRADS sarcoidosis cohorts. Thorax 2024, 79: 1136-1144. PMID: 39117421, DOI: 10.1136/thorax-2023-221095.
- TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.
- GP100 expression is variable in intensity in melanomaMann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.
- Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutationGupta A, Barone C, Quijano E, Piotrowski-Daspit A, Perera J, Riccardi A, Jamali H, Turchick A, Zao W, Saltzman W, Glazer P, Egan M. Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation. Journal Of Cystic Fibrosis 2024 PMID: 39107154, DOI: 10.1016/j.jcf.2024.07.009.
- Development of anex vivo patient-derived tumor model (PDTM) to assess the tumor microenvironment in renal cell carcinoma (RCC)Kashima S, Gupta R, Moritz V, Sadak K, Adeniran A, Humphrey P, Dinulescu D, Palmer D, Hammond S, Bosenberg M, Hurwitz M, Kenney P, Braun D. Development of anex vivo patient-derived tumor model (PDTM) to assess the tumor microenvironment in renal cell carcinoma (RCC). The Oncologist 2024, 29: s5-s6. PMCID: PMC11301923, DOI: 10.1093/oncolo/oyae181.008.
- Spatial transcriptomics reveals organized and distinct immune activation in cutaneous granulomatous disordersDaccache J, Park E, Junejo M, Abdelghaffar M, Hwang E, Mohanty C, Singh C, Wang G, Wheeler J, Shields B, Nelson C, Wang Y, Damsky W. Spatial transcriptomics reveals organized and distinct immune activation in cutaneous granulomatous disorders. Journal Of Allergy And Clinical Immunology 2024, 154: 1216-1231. PMID: 39098508, PMCID: PMC11560686, DOI: 10.1016/j.jaci.2024.07.021.
- LB974 Mutation spectrum of cutaneous vascular anomaliesshah K, Goldust M, Ellis K, Ugwu N, Hu R, Zhou J, Choate K. LB974 Mutation spectrum of cutaneous vascular anomalies. Journal Of Investigative Dermatology 2024, 144: s171. DOI: 10.1016/j.jid.2024.06.1150.
- Adjuvant Everolimus in Non–Clear Cell Renal Cell CarcinomaGulati S, Tangen C, Ryan C, Vaishampayan U, Shuch B, Barata P, Pruthi D, Bergerot C, Tripathi A, Lerner S, Thompson I, Lara P, Pal S. Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma. JAMA Network Open 2024, 7: e2425288. PMID: 39106067, PMCID: PMC11304111, DOI: 10.1001/jamanetworkopen.2024.25288.
- LB946 Spesolimab controls chronic inflammation in GPPKrueger J, Gudjonsson J, Morita A, Lebwohl M, Warren R, Mostaghimi A, Langley R, Tang M, Visvanathan S, Thoma C, Strober B. LB946 Spesolimab controls chronic inflammation in GPP. Journal Of Investigative Dermatology 2024, 144: s165. DOI: 10.1016/j.jid.2024.06.1119.
- 844 Oncogenic Kras converts ERK signal dynamics to disrupt tissue architecture independently of hyperproliferationXin T, Gallini S, Wei H, Gonzalez D, Regot S, Greco V. 844 Oncogenic Kras converts ERK signal dynamics to disrupt tissue architecture independently of hyperproliferation. Journal Of Investigative Dermatology 2024, 144: s147. DOI: 10.1016/j.jid.2024.06.860.
- 586 Molecular mechanism of protein synthesis inhibition in Cutibacterium acnes by clindamycinLomakin I, Devarkar S, Armillei M, Bunick C. 586 Molecular mechanism of protein synthesis inhibition in Cutibacterium acnes by clindamycin. Journal Of Investigative Dermatology 2024, 144: s102. DOI: 10.1016/j.jid.2024.06.602.
- 812 VISTA immune checkpoint is dysregulated in hidradenitis suppurativaKidacki M, Cho C, Lopez-Giraldez F, Jaiswal A, Breidbart R, Damsky W, Vesely M, Chen L. 812 VISTA immune checkpoint is dysregulated in hidradenitis suppurativa. Journal Of Investigative Dermatology 2024, 144: s141. DOI: 10.1016/j.jid.2024.06.828.
- 748 PD-1H/VISTA agonism as a potential therapy for cutaneous lupusVesely M, Garritano J, Damsky W, McNiff J, Chen L. 748 PD-1H/VISTA agonism as a potential therapy for cutaneous lupus. Journal Of Investigative Dermatology 2024, 144: s131. DOI: 10.1016/j.jid.2024.06.764.
- 651 Epigenetic regulation of macrophage activity by glutamine during wound healingXu Y, Forni M, Horsley V. 651 Epigenetic regulation of macrophage activity by glutamine during wound healing. Journal Of Investigative Dermatology 2024, 144: s114. DOI: 10.1016/j.jid.2024.06.667.
- 103 FASNated by fat: WNT signaling activation causes early decline of de-novo lipogenesis leading to lipid depleted dermal adipocytesMadhavan S, Rudolph M, Horsley V, Atit R. 103 FASNated by fat: WNT signaling activation causes early decline of de-novo lipogenesis leading to lipid depleted dermal adipocytes. Journal Of Investigative Dermatology 2024, 144: s18. DOI: 10.1016/j.jid.2024.06.119.
- 656 Wnt signaling activation in mature dermal adipocytes stimulates lipolysis and alters ECM homeostasisMa Q, Segal E, Wyetzner R, Horsley V, Atit R. 656 Wnt signaling activation in mature dermal adipocytes stimulates lipolysis and alters ECM homeostasis. Journal Of Investigative Dermatology 2024, 144: s115. DOI: 10.1016/j.jid.2024.06.672.
- LB862 Psychosocial burden of autoimmune blistering diseases (AIBD): A comprehensive survey studyHoffman V, White M, Yale M, Strong R, Tomayko M. LB862 Psychosocial burden of autoimmune blistering diseases (AIBD): A comprehensive survey study. Journal Of Investigative Dermatology 2024, 144: s150. DOI: 10.1016/j.jid.2024.06.1242.
- LB863 Spatial transcriptomics reveals structurally organized and distinct immune polarization in inflammatory cutaneous granulomatous disordersDaccache J, Park E, Junejo M, Abdelghaffar M, Hwang E, Mohanty C, Singh C, Wang G, Wheeler J, Shields B, Nelson C, Wang Y, Damsky W. LB863 Spatial transcriptomics reveals structurally organized and distinct immune polarization in inflammatory cutaneous granulomatous disorders. Journal Of Investigative Dermatology 2024, 144: s150. DOI: 10.1016/j.jid.2024.06.1243.
- 795 Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cellsBangert C, Alkon N, Chennareddy S, Arnoldner T, Levine J, Pilz M, Ruggiero J, Cohenour E, Jonak C, Damsky W, Griss J, Brunner P. 795 Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Journal Of Investigative Dermatology 2024, 144: s139. DOI: 10.1016/j.jid.2024.06.811.
- 057 Single cell RNA and TCR sequencing reveals hyperexpansion of T cell clones and novel regulatory mechanisms of CD8+ T cells in murine alopcecia areata skin and draining lymph nodesWang Y, Yu W, Micevic G, Daccache J, Wang A, Park K, Wang G, Palmatier M, Wheeler J, King B, Damsky W. 057 Single cell RNA and TCR sequencing reveals hyperexpansion of T cell clones and novel regulatory mechanisms of CD8+ T cells in murine alopcecia areata skin and draining lymph nodes. Journal Of Investigative Dermatology 2024, 144: s10. DOI: 10.1016/j.jid.2024.06.073.
- 059 Industrial compounds mediate allergic sensitizationEisenstein A, Brown-Soler I, Hilliard B, Wang A. 059 Industrial compounds mediate allergic sensitization. Journal Of Investigative Dermatology 2024, 144: s10. DOI: 10.1016/j.jid.2024.06.075.
- Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology.Del Rosso J, Armillei M, Lomakin I, Grada A, Bunick C. Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology. The Journal Of Clinical And Aesthetic Dermatology 2024, 17: 29-40. PMID: 39148960, PMCID: PMC11324192.
- 676 Wnt and SHH interact to determine hair follicle dermal condensate fateJiang Y, Myung P. 676 Wnt and SHH interact to determine hair follicle dermal condensate fate. Journal Of Investigative Dermatology 2024, 144: s118. DOI: 10.1016/j.jid.2024.06.692.
- 029 Investigation of cGAS-STING signaling in scleroderma and GvHD SkinNewton N, Odell A, Odell I. 029 Investigation of cGAS-STING signaling in scleroderma and GvHD Skin. Journal Of Investigative Dermatology 2024, 144: s5. DOI: 10.1016/j.jid.2024.06.045.
- LB931 Treatment of chronic graft-versus-host disease with combination extracorporeal photopheresis and the ROCK2 inhibitor belumosudil can reverse sclerodermatous changesSwallow M, Chang J, Carlson K, Odell I, Girardi M. LB931 Treatment of chronic graft-versus-host disease with combination extracorporeal photopheresis and the ROCK2 inhibitor belumosudil can reverse sclerodermatous changes. Journal Of Investigative Dermatology 2024, 144: s163. DOI: 10.1016/j.jid.2024.06.1104.
- LB941 KM-001, a novel TRPV3 inhibitor, demonstrates safety and preliminary efficacy in Phase 1b clinical study for the treatment of palmoplantar keratodermaCernova J, Eskin-Schwartz M, Atzmony L, Samuelov L, De Brito M, Chan J, Aviezer D, Brener E, Lederman R, Mashriki T, Michel D, Barak S, Braiman L, Sprecher E, O’Toole E. LB941 KM-001, a novel TRPV3 inhibitor, demonstrates safety and preliminary efficacy in Phase 1b clinical study for the treatment of palmoplantar keratoderma. Journal Of Investigative Dermatology 2024, 144: s164. DOI: 10.1016/j.jid.2024.06.1114.
- 412 Persistent cutaneous lesions of darier disease are associated with second-hit somatic variants in ATP2A2 geneAtzmony L, Zagairy F, Tatour Y, Danial-Farran N, Dodiuk-Gad R, Barak E. 412 Persistent cutaneous lesions of darier disease are associated with second-hit somatic variants in ATP2A2 gene. Journal Of Investigative Dermatology 2024, 144: s71. DOI: 10.1016/j.jid.2024.06.428.
- SARS-CoV-2-related bat viruses evade human intrinsic immunity but lack efficient transmission capacityPeña-Hernández M, Alfajaro M, Filler R, Moriyama M, Keeler E, Ranglin Z, Kong Y, Mao T, Menasche B, Mankowski M, Zhao Z, Vogels C, Hahn A, Kalinich C, Zhang S, Huston N, Wan H, Araujo-Tavares R, Lindenbach B, Homer R, Pyle A, Martinez D, Grubaugh N, Israelow B, Iwasaki A, Wilen C. SARS-CoV-2-related bat viruses evade human intrinsic immunity but lack efficient transmission capacity. Nature Microbiology 2024, 9: 2038-2050. PMID: 39075235, DOI: 10.1038/s41564-024-01765-z.
- TRPS1 expression in MPNST is correlated with PRC2 inactivation and loss of H3K27me3Lazcano R, Ingram D, Panse G, Lazar A, Wang W, Cloutier J. TRPS1 expression in MPNST is correlated with PRC2 inactivation and loss of H3K27me3. Human Pathology 2024, 151: 105632. PMID: 39084565, DOI: 10.1016/j.humpath.2024.105632.
- Internal tremors and vibrations in long COVID: a cross-sectional studyZhou T, Sawano M, Arun A, Caraballo C, Michelsen T, McAlpine L, Bhattacharjee B, Lu Y, Khera R, Huang C, Warner F, Herrin J, Iwasaki A, Krumholz H. Internal tremors and vibrations in long COVID: a cross-sectional study. The American Journal Of Medicine 2024 PMID: 39069199, DOI: 10.1016/j.amjmed.2024.07.008.
- Dantrolene corrects cellular disease features of Darier disease and may be a novel treatmentHunt M, Wang N, Pupinyo N, Curman P, Torres M, Jebril W, Chatzinikolaou M, Lorent J, Silberberg G, Bansal R, Burner T, Zhou J, Kimeswenger S, Hoetzenecker W, Choate K, Bachar-Wikstrom E, Wikstrom J. Dantrolene corrects cellular disease features of Darier disease and may be a novel treatment. EMBO Molecular Medicine 2024, 16: 1986-2001. PMID: 39060641, PMCID: PMC11392931, DOI: 10.1038/s44321-024-00104-3.
- #Mohs Surgery: How Mohs Micrographic Surgery Is Portrayed on InstagramImmaneni S, Labadie J, Dover J. #Mohs Surgery: How Mohs Micrographic Surgery Is Portrayed on Instagram. Dermatologic Surgery 2024, 50: 1213-1215. PMID: 39048108, DOI: 10.1097/dss.0000000000004338.
- Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical TrialsGordon K, Thaçi D, Gooderham M, Okubo Y, Strober B, Peterson L, Deherder D, López Pinto J, Gisondi P. Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s404. DOI: 10.25251/skin.8.supp.404.
- Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE TrialsArmstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Colombo M, Vaile J, Vritzali E, Hoyt K, Daamen C, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s406. DOI: 10.25251/skin.8.supp.406.
- Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE TrialsStrober B, Imafuku S, Paul C, Gooderham M, Spelman L, Seo S, Passeron T, Hoyt K, Colombo M, Banerjee S, Augustin M, Stein Gold L, Alexis A, Thaci D, Lebwohl M, Issa N, Cameron M. Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s407. DOI: 10.25251/skin.8.supp.407.
- Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 TrialGottlieb A, Strober B, Kokolakis G, Merola J, Zheng M, Langley R, Tang M, Hofmann P, Thoma C, Warren R. Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s409. DOI: 10.25251/skin.8.supp.409.
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)King B, Senna M, Mesinkovska N, Lynde C, Zirwas M, Maari C, Prajapati V, Sapra S, Brzewski P, Osman L, Hanna S, Wiseman M, Hamilton C, Cassella J. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). Journal Of The American Academy Of Dermatology 2024, 91: 880-888. PMID: 39053611, DOI: 10.1016/j.jaad.2024.06.097.
- Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanomaValdez C, Sánchez-Zuno G, Osmani L, Ibrahim W, Galan A, Bacchiocchi A, Halaban R, Kulkarni R, Kang I, Bucala R, Tran T. Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma. Oncotarget 2024, 15: 507-520. PMID: 39028303, PMCID: PMC11259151, DOI: 10.18632/oncotarget.28615.
- Evolutionary MedicineStearns S, Medzhitov R. Evolutionary Medicine. 2024 DOI: 10.1093/oso/9780192871978.001.0001.
- Pediatric cutaneous Crohn disease: A case series of 89 patients and reviewMcKay G, Liu L, Shaw K, Shakshouk H, Murphy M, Damsky W, Ortega‐Loayza A, Caplan A, Arkin L, Shields B. Pediatric cutaneous Crohn disease: A case series of 89 patients and review. Pediatric Dermatology 2024, 41: 807-813. PMID: 39011834, DOI: 10.1111/pde.15689.
- UBXN3B is crucial for B lymphopoiesisGeng T, Yang D, Lin T, Harrison A, Wang B, Cao Z, Torrance B, Fan Z, Wang K, Wang Y, Yang L, Haynes L, Cheng G, Vella A, Flavell R, Pereira J, Fikrig E, Wang P. UBXN3B is crucial for B lymphopoiesis. EBioMedicine 2024, 106: 105248. PMID: 39018756, PMCID: PMC11287013, DOI: 10.1016/j.ebiom.2024.105248.
- Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinomaTripathi A, Tangen C, Plets M, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Lerner S, Pal S, Shuch B. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU International 2024, 134: 596-601. PMID: 39014969, DOI: 10.1111/bju.16403.
- Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 TrialPlimack E, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross E, Grundy E, Choi W, Dinney C, Lee I, Fong M, Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner S, Flaig T, McConkey D. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. European Urology 2024, 86: 297-300. PMID: 39003201, PMCID: PMC11416320, DOI: 10.1016/j.eururo.2024.06.018.
- Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.Cohen J, Damsky W. Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency. New England Journal Of Medicine 2024, 391: 188-189. PMID: 38986070, DOI: 10.1056/nejmc2404977.